@prefix rr:    <http://www.w3.org/ns/r2rml#> .
@prefix ont:   <http://ontologies.vub.be/oecd#> .
@prefix rdf:   <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .

<http://toxin.vub.be/resource/compound/phenoxyethanol>
        a               ont:Compound ;
        rdfs:label      "phenoxyethanol" ;
        ont:compoundOf  <http://toxin.vub.be/resource/dossier/phenoxyethanol> .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_411/2>
        a                               ont:Test ;
        ont:alanine_aminotransferase    "males in the group receiving 50 mg/kg bw/day showed an increased alat activity at study termination. however, this effect did not show a dose-response relationship, nor was it seen at the other sampling time points. therefore, the effect was not considered to be treatment-related." ;
        ont:aspartate_aminotransferase  "a statistically significant decrease in asat activity was reported for the females of the 150 mg/kg bw/day dose group after 4 weeks of treatment. however, this effect did not show a dose-response relationship, nor was it seen at the other sampling time points. therefore, the effect was not considered to be treatment-related." ;
        ont:changes_skin_fur_eyes_mucous_membranes
                "dermal irritation scores at the site of application revealed sporadic findings of erythema and very slight scaling in male and female rabbits of the 500 mg/kg bw/day dose group. these changes were not associated with gross or histopathological changes and were not considered toxicologically significant." ;
        ont:clinical_observation        "dermal irritation scores at the site of application revealed sporadic findings of erythema and very slight scaling in male and female rabbits of the 500 mg/kg bw/day dose group. these changes were not associated with gross or histopathological changes and were not considered toxicologically significant." ;
        ont:compound                    <http://toxin.vub.be/resource/compound/phenoxyethanol> ;
        ont:compoundLabel               "phenoxyethanol" ;
        ont:guideline                   <http://toxin.vub.be/resource/guideline/OECD%20411> ;
        ont:guidelineLabel              "OECD 411" ;
        ont:haematocrit                 "details of hematology study per dose and per sex avalable in the opinion" ;
        ont:observation_organ_weight_organ_body_weight
                "no treatment-related effects were observed on organ weights or relative organ weights." ;
        ont:type                        "in vivo" .

<http://toxin.vub.be/resource/compound/β-arbutin>
        a               ont:Compound ;
        rdfs:label      "β-arbutin" ;
        ont:compoundOf  <http://toxin.vub.be/resource/dossier/β-arbutin> .

<http://toxin.vub.be/resource/dossier/triclosan>
        a              ont:Report ;
        rdfs:label     "triclosan" ;
        rdfs:seeAlso   <https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf> ;
        ont:contains   <http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_411/1> ;
        ont:guideline  <http://toxin.vub.be/resource/guideline/OECD%20411> .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_411/3>
        a                         ont:Test ;
        ont:changes_skin_fur_eyes_mucous_membranes
                "no substance-related abnormalities were observed in clinical signs" ;
        ont:clinical_observation  "no substance-related abnormalities were observed in clinical signs" ;
        ont:compound              <http://toxin.vub.be/resource/compound/β-arbutin> ;
        ont:compoundLabel         "β-arbutin" ;
        ont:guideline             <http://toxin.vub.be/resource/guideline/OECD%20411> ;
        ont:guidelineLabel        "OECD 411" ;
        ont:observation_behaviour_pattern
                "noel, mg/kg bw/day" ;
        ont:observation_organ_weight_organ_body_weight
                "56 mg/kg bw/day: increased relative weights for spleen, thymus and adrenal gland; 294 mg/kg bw/day: decrease in absolute pituitary gland weight in males; decreased absolute and relative pituitary gland and thymus weights in females; 618 mg/kg bw/day: decreased relative thymus weight." ;
        ont:observation_other_signs_of_toxicity
                "56 mg/kg bw/day: reduced body weight in males week 6-8" ;
        ont:observation_somatomotor_activity
                "618" ;
        ont:total_differential_leucocyte
                "618 mg/kg bw/day: increase in monocyte ratio in females" ;
        ont:type                  "in vivo" .

<http://toxin.vub.be/resource/dossier/phenoxyethanol>
        a              ont:Report ;
        rdfs:label     "phenoxyethanol" ;
        rdfs:seeAlso   <https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_195.pdf> ;
        ont:contains   <http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_411/2> ;
        ont:guideline  <http://toxin.vub.be/resource/guideline/OECD%20411> .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_411/1>
        a                           ont:Test ;
        ont:changes_skin_fur_eyes_mucous_membranes
                "dermal observations of erythema and/or showed oedema in all treated groups. reversal of the dermal effects was seen during the 28-day recovery period." ;
        ont:clinical_observation    "dermal observations of erythema and/or showed oedema in all treated groups. reversal of the dermal effects was seen during the 28-day recovery period." ;
        ont:compound                <http://toxin.vub.be/resource/compound/triclosan> ;
        ont:compoundLabel           "triclosan" ;
        ont:erythrocyte_count       "isolated changes were observed in erythrocyte parameters in high dose animals." ;
        ont:food_water_consumption  "no treatment related changes were found in water consumption and body weight." ;
        ont:guideline               <http://toxin.vub.be/resource/guideline/OECD%20411> ;
        ont:guidelineLabel          "OECD 411" ;
        ont:histopathology_all_gross_lesions
                "histopathology examinations observed eschar and desquamation, hyperplasia/hyperkeratosis of epidermis, dermal inflammation and focal necrosis observed at all doses. " ;
        ont:histopathology_liver    "coagulative necrosis of hepatocytes was also observed. the finding lacked a dose-response." ;
        ont:histopathology_urinary_bladder
                "microscopic changes in the urinary bladder of 3 males were observed. however, it lacked a dose-response. " ;
        ont:observation_ophtalmological_examination
                "no treatment related changes were found in ophthalmoscopic examinations" ;
        ont:observation_organ_weight_organ_body_weight
                "no treatment related changes were found in body weight." ;
        ont:other_enzymes_and_biomarker
                "small but statistically significant changes were observed in some serum chemistry parameters." ;
        ont:type                    "in vivo" .

<http://toxin.vub.be/resource/dossier/β-arbutin>
        a              ont:Report ;
        rdfs:label     "β-arbutin" ;
        rdfs:seeAlso   <http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_169.pdf> ;
        ont:contains   <http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_411/3> ;
        ont:guideline  <http://toxin.vub.be/resource/guideline/OECD%20411> .

<http://toxin.vub.be/resource/compound/triclosan>
        a               ont:Compound ;
        rdfs:label      "triclosan" ;
        ont:compoundOf  <http://toxin.vub.be/resource/dossier/triclosan> .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_411/4>
        a                               ont:Test ;
        ont:changes_skin_fur_eyes_mucous_membranes
                "in the functional observation battery scabs were noted at the application site in about half of the animals in the high dosed group." ;
        ont:clinical_observation        "in the functional observation battery scabs were noted at the application site in about half of the animals in the high dosed group." ;
        ont:compound                    <http://toxin.vub.be/resource/compound/1%2C3%2C5-Triazine%2C%202%2C4%2C6-tris%281%2C1%27-biphenyl%29-4-yl-> ;
        ont:compoundLabel               "1,3,5-Triazine, 2,4,6-tris(1,1'-biphenyl)-4-yl-" ;
        ont:gross_necropsy_abdominal_cavity
                "organ weight changes were recorded in the thymus (decrease) of group 5 males, and the adrenal glands (increase) of group 5 females. although no histopathologic changes were observed in these tissues in rats of this dose group, the changes were considered as nonspecific indicators of a stress-related response." ;
        ont:guideline                   <http://toxin.vub.be/resource/guideline/OECD%20411> ;
        ont:guidelineLabel              "OECD 411" ;
        ont:histopathology_lymph_nodes  "minimal increased lymphocytolysis was recorded in a few rats of groups 5 and 6 (i.e. mainly females of group 5). this finding may reflect a minimal non-specific stress-related response related to the treatment procedure." ;
        ont:observation_autonomic_central_nervous_system
                "clinical signs related to pain, such as abnormal vocalization and/or hyperactivity were observed, mainly from week 5, within the 30-minute period after treatment and generally lasted for less than 30 minutes, in animals given the test item at the high doselevel of 1000 mg/kg bw/day, but mainly in the high-dose group with no protective collar. " ;
        ont:observation_organ_weight_organ_body_weight
                "all males given 1000 mg/kg bw/day (groups 5 and 6) a statistically significantly (p<0.05) lower mean body weight gain was recorded, principally from week 2 and during the whole study period. this effect was reversed during the treatment-free period. mean body weight and mean body weight gains for females of both high dose groups (groups 5 and 6) were similar during the full study period." ;
        ont:type                        "in vivo" .

<http://toxin.vub.be/resource/compound/1%2C3%2C5-Triazine%2C%202%2C4%2C6-tris%281%2C1%27-biphenyl%29-4-yl->
        a               ont:Compound ;
        rdfs:label      "1,3,5-Triazine, 2,4,6-tris(1,1'-biphenyl)-4-yl-" ;
        ont:compoundOf  <http://toxin.vub.be/resource/dossier/1%2C3%2C5-Triazine%2C%202%2C4%2C6-tris%281%2C1%27-biphenyl%29-4-yl-> .

<http://toxin.vub.be/resource/dossier/1%2C3%2C5-Triazine%2C%202%2C4%2C6-tris%281%2C1%27-biphenyl%29-4-yl->
        a              ont:Report ;
        rdfs:label     "1,3,5-Triazine, 2,4,6-tris(1,1'-biphenyl)-4-yl-" ;
        rdfs:seeAlso   <https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_070.pdf> ;
        ont:contains   <http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_411/4> ;
        ont:guideline  <http://toxin.vub.be/resource/guideline/OECD%20411> .
